Maja Zimmer Jakobsen

Ms. Maja Zimmer Jakobsen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
ABAlenka Djarmila Behsen
Alenka Djarmila Behsen
EVEsten Nymoen Vandsemb
Esten Nymoen Vandsemb
TSTobias Schmidt Slørdahl
Tobias Schmidt Slørdahl
Karen DybkærKaren Dybkær
Karen Dybkær
MJMaja Zimmer Jakobsen
Maja Zimmer Jakobsen
KMKristine Misund
Kristine Misund
Overall survival (OS) in multiple myeloma (MM) varies between a couple of months to more than 20 years, influenced by tumor characteristics, the tumor microenvironment (TME), and patient factors such as age and frailty. We analyzed sequential BM samples from 45 MM patients with OS less than 3 years versus more than 8 years using mass cytometry and bulk TCRβ sequencing. Patients with long OS demonstrated stability in the TME and T cell environments, while those with short OS had significant changes at relapse, including fewer T cells, increased Tregs, and more activated and exhausted CD8 + T cells. Notably, higher programmed cell death 1 expression in CD8 + T cells at diagnosis correlated with short OS. Additionally, short-OS patients exhibited a more monoclonal T cell environment at relapse, with abundance of hyperexpanded clones. These findings reveal distinct immune cell differences between patients with short and long OS.

Verified
Journal Article
Open access
PDF file
HDHanne Due
Hanne Due
ABAsta Brogaard
Asta Brogaard
IIIssa Issa
Issa Issa
MJMaja Zimmer Jakobsen
Maja Zimmer Jakobsen
CSCathrine Sylvester
Cathrine Sylvester
Karen DybkærKaren Dybkær
Karen Dybkær
Numerous clinical trials have attempted to improve first-line R-CHOP treatment of diffuse large B-cell lymphoma (DLBCL) through the addition or substitution of drugs. The REMoDL-B trial, testing the addition of bortezomib (RB-CHOP), revealed that ABC and molecular high-grade DLBCL patients benefit from bortezomib. The aim of this study was to achieve a better understanding of the bortezomib response in DLBCL through a functional investigation of clinically identified markers. A retrospective analysis of transcriptional and clinical data from the REMoDL-B trial was conducted to identify genes associated with bortezomib response, identifying CDCA2. DLBCL patients with high expression of CDCA2 had a superior survival outcome when treated with RB-CHOP in comparison to R-CHOP, whereas no difference in outcome was observed for patients with low CDCA2. Moreover, CDCA2 was found to be overexpressed in DLBCL compared to non-malignant tissue, and to have higher levels in GCB and MYC/BCL2 double-expressor patients. Functional in vitro and in vivo studies revealed that knockout of CDCA2 decreased DLBCL cell proliferation and a bortezomib dose–response analysis showed less sensitivity in CDCA2 knockout cells compared to control cells. This study shows that DLBCL patients with high CDCA2 expression benefitted from the addition of bortezomib to R-CHOP and functional studies documented a direct impact of CDCA2 on the bortezomib response in DLBCL cells.